<?xml version="1.0" encoding="UTF-8"?>
<ref id="b0140">
 <label>28</label>
 <element-citation publication-type="journal" id="h0140">
  <person-group person-group-type="author">
   <name>
    <surname>Rut</surname>
    <given-names>S.K.</given-names>
   </name>
   <name>
    <surname>Lv</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Zmudzinski</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Patchett</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Nayak</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Snipas</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>El Oualid</surname>
    <given-names>S.J.</given-names>
   </name>
   <name>
    <surname>Bekes</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Drag</surname>
    <given-names>T.T.</given-names>
   </name>
   <name>
    <surname>Olsen</surname>
    <given-names>M.</given-names>
   </name>
  </person-group>
  <article-title>Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design</article-title>
  <source>bioRxiv</source>
  <year>2020</year>
 </element-citation>
</ref>
